Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

NCT05815173 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT05815173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05815173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Recruiting
Start date
August 1, 2023
Completion date
August 31, 2027
Enrollment
40 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer with kras g12c mutation